CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 39 enrolled
Drug / intervention
Sorafenib (Nexavar, BAY43-9006)drug
Likely dose
Sorafenib (Nexavar, BAY43-9006) 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00586105
NCT00586105Phase 3Completed
CompareCT.gov

A Multicenter Uncontrolled Study of Sorafenib in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma

Bayer·interventional·Posted Jan 4, 2008·Updated Apr 16, 2014

In Brief

A Phase 3 clinical trial evaluating Sorafenib (Nexavar, BAY43-9006) for Carcinoma, Renal Cell. Completed, enrolled 39 participants across 8 sites in 2 countries.

Detailed Summary

A multicenter uncontrolled study of sorafenib in patients with unresectable and/or metastatic renal cell carcinoma (RCC) to assess the pharmacokinetic profile, safety and tolerability, and efficacy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Renal Cell
CountriesChina, Taiwan
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 4, 2008
Enrollment StartDec 1, 2005
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 18.5 years ago

Interventions

Sorafenib (Nexavar, BAY43-9006)drug

400 mg (2 tablets of 200 mg) of sorafenib per oral (PO) twice daily (BID)